Novartis announces commencement of tender offer to acquire Tourmaline Bio
arcticnovartis
Basel, September 29, 2025 – Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding.
Novartis announces commencement of tender offer to acquire Tourmaline Bio
arcticnovartis
Basel, September 29, 2025 – Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding.
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
arcticnovartis
- Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC
- NATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
arcticnovartis
- Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC
- NATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
arcticnovartis
- Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC
- NATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
arcticnovartis
- ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies1
- Following switch to Kesimpta, over 90% of people with RMS showed no evidence of disease activity (NEDA-3) and low annualized relapse rates (ARR) were observed1
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
arcticnovartis
ADDRESS
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
CALL US
+263 (242) 741 308
+263 (242) 741 309
Mon-Fri: 8am – 5pm
